Effects of PACAP on Dry Eye Symptoms, and Possible Use for Therapeutic Application

J Mol Neurosci. 2019 Jul;68(3):420-426. doi: 10.1007/s12031-018-1087-1. Epub 2018 Jun 22.

Abstract

Pituitary adenylate cyclase-activating polypeptide (PACAP) is a 27- or 38-amino acid neuropeptide, which belongs to the vasoactive intestinal polypeptide/glucagon/secretin family of peptides. PACAP and its three receptor subtypes are expressed in neural tissues and in the eye, including the retina, cornea, and lacrimal gland. PACAP is known to exert pleiotropic effects on the central nervous system and in eye tissues where it plays important roles in protecting against dry eye. This review provides an overview of current knowledge regarding dry eye symptoms in aged animals and humans and the protective effects, mechanisms of action. In addition, we also refer to the development of a new preventive/therapeutic method by PACAP of dry eye patients.

Keywords: Aging; Dry eye; Neuroprotective function; PACAP.

Publication types

  • Review

MeSH terms

  • Animals
  • Dry Eye Syndromes / drug therapy*
  • Dry Eye Syndromes / etiology
  • Humans
  • Neuroprotective Agents / therapeutic use*
  • Pituitary Adenylate Cyclase-Activating Polypeptide / therapeutic use*

Substances

  • Neuroprotective Agents
  • Pituitary Adenylate Cyclase-Activating Polypeptide